APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cancer Immunotherapy Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Cancer Immunotherapy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026193 pages

Choose your research edition.

Industry ResearchCancer Immunotherapy Drugs Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Immunotherapy Drugs Industry Growth and Trends Forecast to 2032129 pages · $3,450 USDMarket StructureGlobal Cancer Immunotherapy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Immunotherapy Drugs Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Immunotherapy Drugs Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Cancer Immunotherapy Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Cancer Immunotherapy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cancer Immunotherapy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Immunotherapy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Cancer Immunotherapy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cancer Immunotherapy Drugs include Takeda, Johnson & Johnson, Novartis, Merck KGaA, Roche, Eli Lilly, Pfizer, GSK and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cancer Immunotherapy Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cancer Immunotherapy Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cancer Immunotherapy Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cancer Immunotherapy Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Cancer Immunotherapy Drugs Segment by Company

Takeda

Johnson & Johnson

Novartis

Merck KGaA

Roche

Eli Lilly

Pfizer

GSK

Amgen

AbbVie

AstraZeneca

Seagen

Regeneron

Ono Pharmaceutical

Merck & Co

Innovent

Hengrui Medicine

Gilead Sciences

Exelixis

Bristol-Myers Squibb

Cancer Immunotherapy Drugs Segment by Type

CAR-T Cell Therapy

Cytokine-Based Immunotherapy

Immune Checkpoint Inhibitors

Other

Cancer Immunotherapy Drugs Segment by Application

Blood-related Cancer

Breast Cancer

Prostate Cancer

Lung Cancer

Other

Cancer Immunotherapy Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Immunotherapy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Immunotherapy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Immunotherapy Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cancer Immunotherapy Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cancer Immunotherapy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Cancer Immunotherapy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Cancer Immunotherapy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Cancer Immunotherapy Drugs Industry Trends Table 2. Cancer Immunotherapy Drugs Industry Drivers Table 3. Cancer Immunotherapy Drugs Industry Opportunities and Challenges Table 4. Cancer Immunotherapy Drugs Industry Restraints Table 5. Global Cancer Immunotherapy Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Cancer Immunotherapy Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Cancer Immunotherapy Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Cancer Immunotherapy Drugs Sales Market Share by Manufacturers Table 9. Global Cancer Immunotherapy Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Cancer Immunotherapy Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Cancer Immunotherapy Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Cancer Immunotherapy Drugs Manufacturers, Product Type & Application Table 13. Global Cancer Immunotherapy Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Cancer Immunotherapy Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of CAR-T Cell Therapy Table 17. Major Manufacturers of Cytokine-Based Immunotherapy Table 18. Major Manufacturers of Immune Checkpoint Inhibitors Table 19. Major Manufacturers of Other Table 20. Global Cancer Immunotherapy Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Cancer Immunotherapy Drugs Sales by Type (2021-2026) & (K Units) Table 22. Global Cancer Immunotherapy Drugs Sales by Type (2027-2032) & (K Units) Table 23. Global Cancer Immunotherapy Drugs Sales Market Share by Type (2021-2026) Table 24. Global Cancer Immunotherapy Drugs Sales Market Share by Type (2027-2032) Table 25. Global Cancer Immunotherapy Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Cancer Immunotherapy Drugs Revenue by Type (2021-2026) & (K Units) Table 27. Global Cancer Immunotherapy Drugs Revenue by Type (2027-2032) & (K Units) Table 28. Global Cancer Immunotherapy Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Cancer Immunotherapy Drugs Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Blood-related Cancer Table 31. Major Manufacturers of Breast Cancer Table 32. Major Manufacturers of Prostate Cancer Table 33. Major Manufacturers of Lung Cancer Table 34. Major Manufacturers of Other Table 35. Global Cancer Immunotherapy Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Cancer Immunotherapy Drugs Sales by Application (2021-2026) & (K Units) Table 37. Global Cancer Immunotherapy Drugs Sales by Application (2027-2032) & (K Units) Table 38. Global Cancer Immunotherapy Drugs Sales Market Share by Application (2021-2026) Table 39. Global Cancer Immunotherapy Drugs Sales Market Share by Application (2027-2032) Table 40. Global Cancer Immunotherapy Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Cancer Immunotherapy Drugs Revenue by Application (2021-2026) & (K Units) Table 42. Global Cancer Immunotherapy Drugs Revenue by Application (2027-2032) & (K Units) Table 43. Global Cancer Immunotherapy Drugs Revenue Market Share by Application (2021-2026) Table 44. Global Cancer Immunotherapy Drugs Revenue Market Share by Application (2027-2032) Table 45. Global Cancer Immunotherapy Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Cancer Immunotherapy Drugs Sales by Region (2021-2026) & (K Units) Table 47. Global Cancer Immunotherapy Drugs Sales Market Share by Region (2021-2026) Table 48. Global Cancer Immunotherapy Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global Cancer Immunotherapy Drugs Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Cancer Immunotherapy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units) Table 52. North America Cancer Immunotherapy Drugs Sales by Country (2027-2032) & (K Units) Table 53. Europe Cancer Immunotherapy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units) Table 55. Europe Cancer Immunotherapy Drugs Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific Cancer Immunotherapy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific Cancer Immunotherapy Drugs Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa Cancer Immunotherapy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa Cancer Immunotherapy Drugs Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa Cancer Immunotherapy Drugs Sales by Country (2027-2032) & (K Units) Table 62. Global Cancer Immunotherapy Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Cancer Immunotherapy Drugs Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Cancer Immunotherapy Drugs Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Cancer Immunotherapy Drugs Revenue Market Share by Region (2021-2026) Table 66. Global Cancer Immunotherapy Drugs Revenue Market Share by Region (2027-2032) Table 67. Takeda Company Information Table 68. Takeda Business Overview Table 69. Takeda Cancer Immunotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Takeda Cancer Immunotherapy Drugs Product Portfolio Table 71. Takeda Recent Development Table 72. Johnson & Johnson Company Information Table 73. Johnson & Johnson Business Overview Table 74. Johnson & Johnson Cancer Immunotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Johnson & Johnson Cancer Immunotherapy Drugs Product Portfolio Table 76. Johnson & Johnson Recent Development Table 77. Novartis Company Information Table 78. Novartis Business Overview Table 79. Novartis Cancer Immunotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Novartis Cancer Immunotherapy Drugs Product Portfolio Table 81. Novartis Recent Development Table 82. Merck KGaA Company Information Table 83. Merck KGaA Business Overview Table 84. Merck KGaA Cancer Immunotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Merck KGaA Cancer Immunotherapy Drugs Product Portfolio Table 86. Merck KGaA Recent Development Table 87. Roche Company Information Table 88. Roche Business Overview Table 89. Roche Cancer Immunotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Roche Cancer Immunotherapy Drugs Product Portfolio Table 91. Roche Recent Development Table 92. Eli Lilly Company Information Table 93. Eli Lilly Business Overview Table 94. Eli Lilly Cancer Immunotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Eli Lilly Cancer Immunotherapy Drugs Product Portfolio Table 96. Eli Lilly Recent Development Table 97. Pfizer Company Information Table 98. Pfizer Business Overview Table 99. Pfizer Cancer Immunotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Pfizer Cancer Immunotherapy Drugs Product Portfolio Table 101. Pfizer Recent Development Table 102. GSK Company Information Table 103. GSK Business Overview Table 104. GSK Cancer Immunotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. GSK Cancer Immunotherapy Drugs Product Portfolio Table 106. GSK Recent Development Table 107. Amgen Company Information Table 108. Amgen Business Overview Table 109. Amgen Cancer Immunotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Amgen Cancer Immunotherapy Drugs Product Portfolio Table 111. Amgen Recent Development Table 112. AbbVie Company Information Table 113. AbbVie Business Overview Table 114. AbbVie Cancer Immunotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. AbbVie Cancer Immunotherapy Drugs Product Portfolio Table 116. AbbVie Recent Development Table 117. AstraZeneca Company Information Table 118. AstraZeneca Business Overview Table 119. AstraZeneca Cancer Immunotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. AstraZeneca Cancer Immunotherapy Drugs Product Portfolio Table 121. AstraZeneca Recent Development Table 122. Seagen Company Information Table 123. Seagen Business Overview Table 124. Seagen Cancer Immunotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Seagen Cancer Immunotherapy Drugs Product Portfolio Table 126. Seagen Recent Development Table 127. Regeneron Company Information Table 128. Regeneron Business Overview Table 129. Regeneron Cancer Immunotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Regeneron Cancer Immunotherapy Drugs Product Portfolio Table 131. Regeneron Recent Development Table 132. Ono Pharmaceutical Company Information Table 133. Ono Pharmaceutical Business Overview Table 134. Ono Pharmaceutical Cancer Immunotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Ono Pharmaceutical Cancer Immunotherapy Drugs Product Portfolio Table 136. Ono Pharmaceutical Recent Development Table 137. Merck & Co Company Information Table 138. Merck & Co Business Overview Table 139. Merck & Co Cancer Immunotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. Merck & Co Cancer Immunotherapy Drugs Product Portfolio Table 141. Merck & Co Recent Development Table 142. Innovent Company Information Table 143. Innovent Business Overview Table 144. Innovent Cancer Immunotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 145. Innovent Cancer Immunotherapy Drugs Product Portfolio Table 146. Innovent Recent Development Table 147. Hengrui Medicine Company Information Table 148. Hengrui Medicine Business Overview Table 149. Hengrui Medicine Cancer Immunotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 150. Hengrui Medicine Cancer Immunotherapy Drugs Product Portfolio Table 151. Hengrui Medicine Recent Development Table 152. Gilead Sciences Company Information Table 153. Gilead Sciences Business Overview Table 154. Gilead Sciences Cancer Immunotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 155. Gilead Sciences Cancer Immunotherapy Drugs Product Portfolio Table 156. Gilead Sciences Recent Development Table 157. Exelixis Company Information Table 158. Exelixis Business Overview Table 159. Exelixis Cancer Immunotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 160. Exelixis Cancer Immunotherapy Drugs Product Portfolio Table 161. Exelixis Recent Development Table 162. Bristol-Myers Squibb Company Information Table 163. Bristol-Myers Squibb Business Overview Table 164. Bristol-Myers Squibb Cancer Immunotherapy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 165. Bristol-Myers Squibb Cancer Immunotherapy Drugs Product Portfolio Table 166. Bristol-Myers Squibb Recent Development Table 167. Key Raw Materials Table 168. Raw Materials Key Suppliers Table 169. Cancer Immunotherapy Drugs Distributors List Table 170. Cancer Immunotherapy Drugs Customers List Table 171. Research Programs/Design for This Report Table 172. Authors List of This Report Table 173. Secondary Sources Table 174. Primary Sources List of Figures Figure 1. Cancer Immunotherapy Drugs Product Image Figure 2. Global Cancer Immunotherapy Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Immunotherapy Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Cancer Immunotherapy Drugs Sales (2021-2032) & (K Units) Figure 5. Global Cancer Immunotherapy Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Cancer Immunotherapy Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. CAR-T Cell Therapy Image Figure 9. Cytokine-Based Immunotherapy Image Figure 10. Immune Checkpoint Inhibitors Image Figure 11. Other Image Figure 12. Global Cancer Immunotherapy Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Cancer Immunotherapy Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Cancer Immunotherapy Drugs Sales Market Share by Type (2021-2032) Figure 15. Global Cancer Immunotherapy Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Cancer Immunotherapy Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Cancer Immunotherapy Drugs Revenue Market Share by Type (2021-2032) Figure 18. Blood-related Cancer Image Figure 19. Breast Cancer Image Figure 20. Prostate Cancer Image Figure 21. Lung Cancer Image Figure 22. Other Image Figure 23. Global Cancer Immunotherapy Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Cancer Immunotherapy Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Cancer Immunotherapy Drugs Sales Market Share by Application (2021-2032) Figure 26. Global Cancer Immunotherapy Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Cancer Immunotherapy Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Cancer Immunotherapy Drugs Revenue Market Share by Application (2021-2032) Figure 29. North America Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America Cancer Immunotherapy Drugs Sales Market Share by Country (2021-2032) Figure 31. U.S. Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Cancer Immunotherapy Drugs Sales Market Share by Country (2021-2032) Figure 36. Germany Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Cancer Immunotherapy Drugs Sales Market Share by Country (2021-2032) Figure 43. China Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Cancer Immunotherapy Drugs Sales Market Share by Country (2021-2032) Figure 51. Brazil Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile Cancer Immunotherapy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global Cancer Immunotherapy Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Cancer Immunotherapy Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Figure 62. North America Cancer Immunotherapy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Europe Cancer Immunotherapy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Cancer Immunotherapy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Cancer Immunotherapy Drugs Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Cancer Immunotherapy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Cancer Immunotherapy Drugs Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Cancer Immunotherapy Drugs Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • CAR-T Cell Therapy
  • Cytokine-Based Immunotherapy
  • Immune Checkpoint Inhibitors
  • Other
Applications
  • Blood-related Cancer
  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Other
Companies covered
  • Takeda
  • Johnson & Johnson
  • Novartis
  • Merck KGaA
  • Roche
  • Eli Lilly
  • Pfizer
  • GSK
  • Amgen
  • AbbVie
  • AstraZeneca
  • Seagen
  • Regeneron
  • Ono Pharmaceutical
  • Merck & Co
  • Innovent
  • Hengrui Medicine
  • Gilead Sciences
  • Exelixis
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cancer Immunotherapy Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cancer Immunotherapy Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Cancer Immunotherapy Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Cancer Immunotherapy Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Cancer Immunotherapy Drugs Market Dynamics
  1. 2.1 Cancer Immunotherapy Drugs Industry Trends
  2. 2.2 Cancer Immunotherapy Drugs Industry Drivers
  3. 2.3 Cancer Immunotherapy Drugs Industry Opportunities and Challenges
  4. 2.4 Cancer Immunotherapy Drugs Industry Restraints
3 Cancer Immunotherapy Drugs Market by Manufacturers
  1. 3.1 Global Cancer Immunotherapy Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Cancer Immunotherapy Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Cancer Immunotherapy Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Cancer Immunotherapy Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cancer Immunotherapy Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Cancer Immunotherapy Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Cancer Immunotherapy Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cancer Immunotherapy Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cancer Immunotherapy Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cancer Immunotherapy Drugs Tier 1, Tier 2, and Tier 3
4 Cancer Immunotherapy Drugs Market by Type
  1. 4.1 Cancer Immunotherapy Drugs Type Introduction
  2. 4.1.1 CAR-T Cell Therapy
  3. 4.1.2 Cytokine-Based Immunotherapy
  4. 4.1.3 Immune Checkpoint Inhibitors
  5. 4.1.4 Other
  6. 4.2 Global Cancer Immunotherapy Drugs Sales by Type
  7. 4.2.1 Global Cancer Immunotherapy Drugs Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Cancer Immunotherapy Drugs Sales by Type (2021-2032)
  9. 4.2.3 Global Cancer Immunotherapy Drugs Sales Market Share by Type (2021-2032)
  10. 4.3 Global Cancer Immunotherapy Drugs Revenue by Type
  11. 4.3.1 Global Cancer Immunotherapy Drugs Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Cancer Immunotherapy Drugs Revenue by Type (2021-2032)
  13. 4.3.3 Global Cancer Immunotherapy Drugs Revenue Market Share by Type (2021-2032)
5 Cancer Immunotherapy Drugs Market by Application
  1. 5.1 Cancer Immunotherapy Drugs Application Introduction
  2. 5.1.1 Blood-related Cancer
  3. 5.1.2 Breast Cancer
  4. 5.1.3 Prostate Cancer
  5. 5.1.4 Lung Cancer
  6. 5.1.5 Other
  7. 5.2 Global Cancer Immunotherapy Drugs Sales by Application
  8. 5.2.1 Global Cancer Immunotherapy Drugs Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Cancer Immunotherapy Drugs Sales by Application (2021-2032)
  10. 5.2.3 Global Cancer Immunotherapy Drugs Sales Market Share by Application (2021-2032)
  11. 5.3 Global Cancer Immunotherapy Drugs Revenue by Application
  12. 5.3.1 Global Cancer Immunotherapy Drugs Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Cancer Immunotherapy Drugs Revenue by Application (2021-2032)
  14. 5.3.3 Global Cancer Immunotherapy Drugs Revenue Market Share by Application (2021-2032)
6 Global Cancer Immunotherapy Drugs Sales by Region
  1. 6.1 Global Cancer Immunotherapy Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cancer Immunotherapy Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Cancer Immunotherapy Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Cancer Immunotherapy Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cancer Immunotherapy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Cancer Immunotherapy Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Cancer Immunotherapy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Cancer Immunotherapy Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Cancer Immunotherapy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Cancer Immunotherapy Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Cancer Immunotherapy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Cancer Immunotherapy Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Cancer Immunotherapy Drugs Revenue by Region
  1. 7.1 Global Cancer Immunotherapy Drugs Revenue by Region
  2. 7.1.1 Global Cancer Immunotherapy Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Cancer Immunotherapy Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Cancer Immunotherapy Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Cancer Immunotherapy Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Cancer Immunotherapy Drugs Revenue (2021-2032)
  8. 7.2.2 North America Cancer Immunotherapy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Cancer Immunotherapy Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Cancer Immunotherapy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Cancer Immunotherapy Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Cancer Immunotherapy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Cancer Immunotherapy Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Cancer Immunotherapy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Cancer Immunotherapy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Cancer Immunotherapy Drugs Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Cancer Immunotherapy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Cancer Immunotherapy Drugs Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Cancer Immunotherapy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Cancer Immunotherapy Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck KGaA
  20. 8.4.1 Merck KGaA Company Information
  21. 8.4.2 Merck KGaA Business Overview
  22. 8.4.3 Merck KGaA Cancer Immunotherapy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck KGaA Cancer Immunotherapy Drugs Product Portfolio
  24. 8.4.5 Merck KGaA Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Cancer Immunotherapy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche Cancer Immunotherapy Drugs Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Eli Lilly
  32. 8.6.1 Eli Lilly Company Information
  33. 8.6.2 Eli Lilly Business Overview
  34. 8.6.3 Eli Lilly Cancer Immunotherapy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly Cancer Immunotherapy Drugs Product Portfolio
  36. 8.6.5 Eli Lilly Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Cancer Immunotherapy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Cancer Immunotherapy Drugs Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 GSK
  44. 8.8.1 GSK Company Information
  45. 8.8.2 GSK Business Overview
  46. 8.8.3 GSK Cancer Immunotherapy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GSK Cancer Immunotherapy Drugs Product Portfolio
  48. 8.8.5 GSK Recent Developments
  49. 8.9 Amgen
  50. 8.9.1 Amgen Company Information
  51. 8.9.2 Amgen Business Overview
  52. 8.9.3 Amgen Cancer Immunotherapy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Amgen Cancer Immunotherapy Drugs Product Portfolio
  54. 8.9.5 Amgen Recent Developments
  55. 8.10 AbbVie
  56. 8.10.1 AbbVie Company Information
  57. 8.10.2 AbbVie Business Overview
  58. 8.10.3 AbbVie Cancer Immunotherapy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AbbVie Cancer Immunotherapy Drugs Product Portfolio
  60. 8.10.5 AbbVie Recent Developments
  61. 8.11 AstraZeneca
  62. 8.11.1 AstraZeneca Company Information
  63. 8.11.2 AstraZeneca Business Overview
  64. 8.11.3 AstraZeneca Cancer Immunotherapy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 AstraZeneca Cancer Immunotherapy Drugs Product Portfolio
  66. 8.11.5 AstraZeneca Recent Developments
  67. 8.12 Seagen
  68. 8.12.1 Seagen Company Information
  69. 8.12.2 Seagen Business Overview
  70. 8.12.3 Seagen Cancer Immunotherapy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Seagen Cancer Immunotherapy Drugs Product Portfolio
  72. 8.12.5 Seagen Recent Developments
  73. 8.13 Regeneron
  74. 8.13.1 Regeneron Company Information
  75. 8.13.2 Regeneron Business Overview
  76. 8.13.3 Regeneron Cancer Immunotherapy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Regeneron Cancer Immunotherapy Drugs Product Portfolio
  78. 8.13.5 Regeneron Recent Developments
  79. 8.14 Ono Pharmaceutical
  80. 8.14.1 Ono Pharmaceutical Company Information
  81. 8.14.2 Ono Pharmaceutical Business Overview
  82. 8.14.3 Ono Pharmaceutical Cancer Immunotherapy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Ono Pharmaceutical Cancer Immunotherapy Drugs Product Portfolio
  84. 8.14.5 Ono Pharmaceutical Recent Developments
  85. 8.15 Merck & Co
  86. 8.15.1 Merck & Co Company Information
  87. 8.15.2 Merck & Co Business Overview
  88. 8.15.3 Merck & Co Cancer Immunotherapy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Merck & Co Cancer Immunotherapy Drugs Product Portfolio
  90. 8.15.5 Merck & Co Recent Developments
  91. 8.16 Innovent
  92. 8.16.1 Innovent Company Information
  93. 8.16.2 Innovent Business Overview
  94. 8.16.3 Innovent Cancer Immunotherapy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Innovent Cancer Immunotherapy Drugs Product Portfolio
  96. 8.16.5 Innovent Recent Developments
  97. 8.17 Hengrui Medicine
  98. 8.17.1 Hengrui Medicine Company Information
  99. 8.17.2 Hengrui Medicine Business Overview
  100. 8.17.3 Hengrui Medicine Cancer Immunotherapy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Hengrui Medicine Cancer Immunotherapy Drugs Product Portfolio
  102. 8.17.5 Hengrui Medicine Recent Developments
  103. 8.18 Gilead Sciences
  104. 8.18.1 Gilead Sciences Company Information
  105. 8.18.2 Gilead Sciences Business Overview
  106. 8.18.3 Gilead Sciences Cancer Immunotherapy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Gilead Sciences Cancer Immunotherapy Drugs Product Portfolio
  108. 8.18.5 Gilead Sciences Recent Developments
  109. 8.19 Exelixis
  110. 8.19.1 Exelixis Company Information
  111. 8.19.2 Exelixis Business Overview
  112. 8.19.3 Exelixis Cancer Immunotherapy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Exelixis Cancer Immunotherapy Drugs Product Portfolio
  114. 8.19.5 Exelixis Recent Developments
  115. 8.20 Bristol-Myers Squibb
  116. 8.20.1 Bristol-Myers Squibb Company Information
  117. 8.20.2 Bristol-Myers Squibb Business Overview
  118. 8.20.3 Bristol-Myers Squibb Cancer Immunotherapy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Bristol-Myers Squibb Cancer Immunotherapy Drugs Product Portfolio
  120. 8.20.5 Bristol-Myers Squibb Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cancer Immunotherapy Drugs Value Chain Analysis
  2. 9.1.1 Cancer Immunotherapy Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cancer Immunotherapy Drugs Production Mode & Process
  6. 9.2 Cancer Immunotherapy Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cancer Immunotherapy Drugs Distributors
  9. 9.2.3 Cancer Immunotherapy Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst